Marco Basso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marco Basso has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Sperotto
Veneto Institute of Oncology, Padua, Italy, Italy
4 shared publications - Federico De Marchi
Oncology-Veneto Institute of Oncology, Veneto Institute of Oncology, Padua, Italy, Italy
4 shared publications - Michele Gottardi
Oncology-Veneto Institute of Oncology, Veneto Institute of Oncology, Padua, Italy, Italy
4 shared publications - Roberta De Marchi
UOSD Terapie Cellulari, Dipartimento di Oncologia, Istituto Oncologico Veneto (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 35128 Padua, Italy
4 shared publications - Giulia Ciotti
UOSD Terapie Cellulari, Dipartimento di Oncologia, Istituto Oncologico Veneto (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 35128 Padua, Italy
3 shared publications - Alessandro Atanasio
Istituto Oncologico Veneto, Padua, Italy, Italy
2 shared publications
Latest Publications
- Open Access
Maintenance Therapy After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: Still an Open Question?
Disease relapse remains the leading cause of treatment failure in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This narrative review, searched from Pubmed, from 2015 to 2026, critically synthesizes the available evidence on post-transplant maintenance strategies, which have evolved over the past three decades from conventional chemotherapy to molecularly targeted agents and interventions aimed at modulating antileukemic immunity. Particular attention is given to the biological rationale, efficacy, safety, and clinical applicability of these approaches, as well as to the substantial heterogeneity in study design, patient selection, and treatment initiation and duration. The available evidence indicates that the potential benefit of maintenance is unlikely to be uniform across all recipients and should be interpreted in relation to AML molecular features, baseline relapse risk, prior treatment exposure, measurable residual disease status, expected toxicity, and the patient’s overall clinical condition. Although selected strategies may prolong remission and improve survival, the optimal agent, timing, duration, and target population remain incompletely defined. Current evidence therefore supports a risk-adapted and molecularly informed approach, while underscoring the need for adequately powered prospective studies using standardized endpoints and incorporating quality-of-life outcomes.
Open AccessMaintenance Therapy After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: Still an Open Question?
Disease relapse remains the leading cause of treatment failure in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This narrative review, searched from Pubmed, from 2015 to 2026, critically synthesizes the available evidence on post-transplant maintenance strategies, which have evolved over the past three decades from conventional chemotherapy to molecularly targeted agents and interventions aimed at modulating antileukemic immunity. Particular attention is given to the biological rationale, efficacy, safety, and clinical applicability of these approaches, as well as to the substantial heterogeneity in study design, patient selection, and treatment initiation and duration. The available evidence indicates that the potential benefit of maintenance is unlikely to be uniform across all recipients and should be interpreted in relation to AML molecular features, baseline relapse risk, prior treatment exposure, measurable residual disease status, expected toxicity, and the patient’s overall clinical condition. Although selected strategies may prolong remission and improve survival, the optimal agent, timing, duration, and target population remain incompletely defined. Current evidence therefore supports a risk-adapted and molecularly informed approach, while underscoring the need for adequately powered prospective studies using standardized endpoints and incorporating quality-of-life outcomes.
- Open Access
- 29 September 2026
- Published by MDPI AG in Preprints.org
Maintenance Therapy After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: Still an Open Question?
Disease relapse remains the leading cause of treatment failure in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This systematic review critically synthesizes the available evidence on post-transplant maintenance strategies, which have evolved over the past three decades from conventional chemotherapy to molecularly targeted agents and interventions aimed at modulating antileukemic immunity. Particular attention is given to the biological rationale, efficacy, safety, and clinical applicability of these approaches, as well as to the substantial heterogeneity in study design, patient selection, treatment initiation, and duration. The available evidence indicates that the potential benefit of maintenance is unlikely to be uniform across all recipients and should be interpreted in relation to AML molecular features, baseline relapse risk, prior treatment exposure, measurable residual disease status, expected toxicity, and the patient’s overall clinical condition. Although selected strategies may prolong remission and improve survival, the optimal agent, timing, duration, and target population remain incompletely defined. Current evidence therefore supports a risk-adapted and molecularly informed approach, while underscoring the need for adequately powered prospective studies using standardized endpoints and incorporating quality-of-life outcomes.
- 29 September 2026
- Published by MDPI AG in Preprints.org
Open AccessMaintenance Therapy After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: Still an Open Question?
Disease relapse remains the leading cause of treatment failure in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This systematic review critically synthesizes the available evidence on post-transplant maintenance strategies, which have evolved over the past three decades from conventional chemotherapy to molecularly targeted agents and interventions aimed at modulating antileukemic immunity. Particular attention is given to the biological rationale, efficacy, safety, and clinical applicability of these approaches, as well as to the substantial heterogeneity in study design, patient selection, treatment initiation, and duration. The available evidence indicates that the potential benefit of maintenance is unlikely to be uniform across all recipients and should be interpreted in relation to AML molecular features, baseline relapse risk, prior treatment exposure, measurable residual disease status, expected toxicity, and the patient’s overall clinical condition. Although selected strategies may prolong remission and improve survival, the optimal agent, timing, duration, and target population remain incompletely defined. Current evidence therefore supports a risk-adapted and molecularly informed approach, while underscoring the need for adequately powered prospective studies using standardized endpoints and incorporating quality-of-life outcomes.
- Open Access
- 27 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (8) , 1679
The Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukemic growth, but can actively shape AML initiation, maintenance, and treatment resistance. Clinical observations such as donor cell leukemia after allogeneic transplantation, together with experimental models in which stromal or osteolineage abnormalities induce myeloid disease, suggest that altered niches may contribute to leukemogenesis in selected settings. In established AML, vascular and endosteal compartments provide adhesive, chemokine, inflammatory, and metabolic signals that promote leukemic-cell retention, quiescence, survival, and chemotherapy tolerance. AML cells also remodel the surrounding marrow, suppressing normal hematopoiesis and generating stromal, endothelial, osteoblastic, adipocytic, and immune-cell programs that favor leukemic persistence. These interactions are especially relevant to drug resistance, including resistance to venetoclax-based therapy, where cytokine-mediated changes in apoptotic dependence, fatty-acid metabolism, mitochondrial adaptation, and stromal support may all contribute. Several therapeutic approaches have attempted to disrupt niche-mediated protection, including targeting CXCL12/CXCR4 signaling, adhesion pathways, inflammatory circuits, Hedgehog signaling, and metabolic dependencies. Although early-phase studies have shown activity in some AML subsets, randomized evidence remains limited and results have been inconsistent. We discuss how a better understanding of microenvironmental biology may help define when niche-directed therapy is most likely to complement conventional and molecularly targeted AML treatment.
- 27 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (8) , 1679
Open AccessThe Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukemic growth, but can actively shape AML initiation, maintenance, and treatment resistance. Clinical observations such as donor cell leukemia after allogeneic transplantation, together with experimental models in which stromal or osteolineage abnormalities induce myeloid disease, suggest that altered niches may contribute to leukemogenesis in selected settings. In established AML, vascular and endosteal compartments provide adhesive, chemokine, inflammatory, and metabolic signals that promote leukemic-cell retention, quiescence, survival, and chemotherapy tolerance. AML cells also remodel the surrounding marrow, suppressing normal hematopoiesis and generating stromal, endothelial, osteoblastic, adipocytic, and immune-cell programs that favor leukemic persistence. These interactions are especially relevant to drug resistance, including resistance to venetoclax-based therapy, where cytokine-mediated changes in apoptotic dependence, fatty-acid metabolism, mitochondrial adaptation, and stromal support may all contribute. Several therapeutic approaches have attempted to disrupt niche-mediated protection, including targeting CXCL12/CXCR4 signaling, adhesion pathways, inflammatory circuits, Hedgehog signaling, and metabolic dependencies. Although early-phase studies have shown activity in some AML subsets, randomized evidence remains limited and results have been inconsistent. We discuss how a better understanding of microenvironmental biology may help define when niche-directed therapy is most likely to complement conventional and molecularly targeted AML treatment.
- Open Access
- 9 June 2026
- Published by MDPI AG in Preprints.org
The Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem-cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukemic growth, but can actively shape AML initiation, maintenance, and treatment resistance. Clinical observations such as donor cell leukemia after allogeneic transplantation, together with experimental models in which stromal or osteolineage abnormalities induce myeloid disease, suggest that altered niches may contribute to leukemogenesis in selected settings. In established AML, vascular and endosteal compartments provide adhesive, chemokine, inflammatory, and metabolic signals that promote leukemic-cell retention, quiescence, survival, and chemotherapy tolerance. AML cells also remodel the surrounding marrow, suppressing normal hematopoiesis and generating stromal, endothelial, osteoblastic, adipocytic, and immune-cell programs that favor leukemic persistence. These interactions are especially relevant to drug resistance, including resistance to venetoclax-based therapy, where cytokine-mediated changes in apoptotic dependence, fatty-acid metabolism, mitochondrial adaptation, and stromal support may all contribute. Several therapeutic approaches have attempted to disrupt niche-mediated protection, including targeting CXCL12/CXCR4 signaling, adhesion pathways, inflammatory circuits, Hedgehog signaling, and metabolic dependencies. Although early-phase studies have shown activity in some AML subsets, randomized evidence remains limited and results have been inconsistent. We discuss how a better understanding of microenvironmental biology may help define when niche-directed therapy is most likely to complement conventional and molecularly targeted AML treatment.
- 9 June 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem-cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukemic growth, but can actively shape AML initiation, maintenance, and treatment resistance. Clinical observations such as donor cell leukemia after allogeneic transplantation, together with experimental models in which stromal or osteolineage abnormalities induce myeloid disease, suggest that altered niches may contribute to leukemogenesis in selected settings. In established AML, vascular and endosteal compartments provide adhesive, chemokine, inflammatory, and metabolic signals that promote leukemic-cell retention, quiescence, survival, and chemotherapy tolerance. AML cells also remodel the surrounding marrow, suppressing normal hematopoiesis and generating stromal, endothelial, osteoblastic, adipocytic, and immune-cell programs that favor leukemic persistence. These interactions are especially relevant to drug resistance, including resistance to venetoclax-based therapy, where cytokine-mediated changes in apoptotic dependence, fatty-acid metabolism, mitochondrial adaptation, and stromal support may all contribute. Several therapeutic approaches have attempted to disrupt niche-mediated protection, including targeting CXCL12/CXCR4 signaling, adhesion pathways, inflammatory circuits, Hedgehog signaling, and metabolic dependencies. Although early-phase studies have shown activity in some AML subsets, randomized evidence remains limited and results have been inconsistent. We discuss how a better understanding of microenvironmental biology may help define when niche-directed therapy is most likely to complement conventional and molecularly targeted AML treatment.
- Open Access
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape
- 9 December 2022
- Published by Springer Nature in Bulletin of Environmental Contamination and Toxicology
- Vol. 110 (1) , 1-7
Seabirds as Biomonitors of Mercury Bioavailability in the Venice Lagoon
Seabirds accumulate mercury (Hg) due to their long-life span together with their high trophic position. A Hg monitoring in Venice’s Lagoon using three seabird species occupying different trophic habitat (Thalasseus sandvicensis, Ichthyaetus melanocephalus, and Chroicocephalus ridibundus) confirmed that fledgelings might effectively be used as sentinels of Hg bioavailability. The significant differences in Hg residues in feathers observed among the species highlighted a possible differential exposure due to different diets, with C. ridibundus accumulating more Hg than the other species. Average residues in feathers were not above the threshold associated with adverse effects on birds (5 mg kg− 1). Nevertheless, a large part of the C. ridibundus individuals (58%) exceeded the adverse effect level, underlining the need for strengthening Hg monitoring. Seabirds indeed may provide relevant insight on Hg transfer in food webs and a better picture of the hazards to men when bird species forage on species exploited for human consumption.
- 9 December 2022
- Published by Springer Nature in Bulletin of Environmental Contamination and Toxicology
- Vol. 110 (1) , 1-7
Seabirds as Biomonitors of Mercury Bioavailability in the Venice Lagoon
Seabirds accumulate mercury (Hg) due to their long-life span together with their high trophic position. A Hg monitoring in Venice’s Lagoon using three seabird species occupying different trophic habitat (Thalasseus sandvicensis, Ichthyaetus melanocephalus, and Chroicocephalus ridibundus) confirmed that fledgelings might effectively be used as sentinels of Hg bioavailability. The significant differences in Hg residues in feathers observed among the species highlighted a possible differential exposure due to different diets, with C. ridibundus accumulating more Hg than the other species. Average residues in feathers were not above the threshold associated with adverse effects on birds (5 mg kg− 1). Nevertheless, a large part of the C. ridibundus individuals (58%) exceeded the adverse effect level, underlining the need for strengthening Hg monitoring. Seabirds indeed may provide relevant insight on Hg transfer in food webs and a better picture of the hazards to men when bird species forage on species exploited for human consumption.
- Open Access
Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
Background: Rituximab plus bendamustine (BR), and rituximab, bendamustine, and cytarabine (R-BAC) are well-known induction therapies in elderly patients with mantle cell lymphoma (MCL), according to clinical guidelines. However, a direct comparison between the two regimens has never been performed. Methods: In this multicentre retrospective study, we compared the outcome of patients with newly diagnosed MCL, treated with BR or R-BAC. Primary endpoint was 2-year progression-free survival (PFS). Inclusion bias was assessed using a propensity score stratified by gender, age, MCL morphology, and MIPI score. Results: After adjusting by propensity score, we identified 156 patients (53 BR, 103 R-BAC) with median age of 72 (53–90). Median follow-up was 46 months (range 12–133). R-BAC was administered in a 2-day schedule or with attenuated dose in 51% of patients. Patients treated with R-BAC achieved CR in 91% of cases, as compared with 60% for BR (p < 0.0001). The 2-year PFS was 87 ± 3% and 64 ± 7% for R-BAC and BR, respectively (p = 0.001). In terms of toxicity, R-BAC was associated with significantly more pronounced grade 3–4 thrombocytopenia than BR (50% vs. 17%). Conclusions: This study indicates that R-BAC, even when administered with judiciously attenuated doses, is associated with significantly prolonged 2-year PFS than BR in elderly patients with previously untreated MCL.
Open AccessRituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
Background: Rituximab plus bendamustine (BR), and rituximab, bendamustine, and cytarabine (R-BAC) are well-known induction therapies in elderly patients with mantle cell lymphoma (MCL), according to clinical guidelines. However, a direct comparison between the two regimens has never been performed. Methods: In this multicentre retrospective study, we compared the outcome of patients with newly diagnosed MCL, treated with BR or R-BAC. Primary endpoint was 2-year progression-free survival (PFS). Inclusion bias was assessed using a propensity score stratified by gender, age, MCL morphology, and MIPI score. Results: After adjusting by propensity score, we identified 156 patients (53 BR, 103 R-BAC) with median age of 72 (53–90). Median follow-up was 46 months (range 12–133). R-BAC was administered in a 2-day schedule or with attenuated dose in 51% of patients. Patients treated with R-BAC achieved CR in 91% of cases, as compared with 60% for BR (p < 0.0001). The 2-year PFS was 87 ± 3% and 64 ± 7% for R-BAC and BR, respectively (p = 0.001). In terms of toxicity, R-BAC was associated with significantly more pronounced grade 3–4 thrombocytopenia than BR (50% vs. 17%). Conclusions: This study indicates that R-BAC, even when administered with judiciously attenuated doses, is associated with significantly prolonged 2-year PFS than BR in elderly patients with previously untreated MCL.